The invasiveness of glioma cells, a major cause of mortality in malignant brain tumors, is mediated in part by the cellular microenvironment. We have reported that in a three-dimensional matrix of type 1 collagen (3D-CL) gel, the extracellular matrix protein tenascin-C (TN) increased the invasiveness of glioma cells through the downstream production of matrix metalloproteinase (MMP)-12. In the present study, we have investigated the signaling mechanisms involved in the TN-stimulated glioma invasiveness. We found that the pan protein kinase C (PKC) inhibitor, bisindolylmaleimide I, decreased TN-enhanced glioma invasion in 3D-CL. Calphostin C, an inhibitor of conventional and novel PKC isozymes, and the relatively selective PKCd inhibitor rottlerin decreased TN-stimulated glioma invasiveness in a concentration-and time-dependent manner. These findings of the possible involvement of PKCd was supported by its translocation from the cytosol to membrane fraction in 3D-CL gel supplemented with TN as detected by western blot assays and immunofluorescence microscopy and by elevation of PKCd enzyme activity. Moreover, pharmacological blockade of PKCd decreased MMP-12 levels and glioma invasiveness. Finally, small interfering RNA to PKCd reduced TN-stimulated glioma invasiveness concurrent with decreased MMP-12 production. Our results implicate PKCd as a therapeutic target to reduce MMP-12 expression and glioma invasiveness when tumor cells are stimulated by the TN-enriched glioma microenvironment.
Introduction
The dismal outcome of patients with malignant gliomas is attributed to the highly invasive nature of tumor cells into surrounding normal brain tissue leading to new areas of multifoci growth. The invasiveness of glioma cells is mediated in part by their interaction with surrounding astrocytes (1) and with the extracellular matrix (ECM) (2-4), followed by degradation of ECM by proteases, particularly the matrix metalloproteinases (MMPs) (5) (6) (7) (8) . With regards to ECM components surrounding brain tumors, several have been described including tenascin-C (TN), collagens, fibronectin and proteoglycans. A particularly prominent ECM component in glioma pathophysiology is TN, and its expression level correlates inversely with prognosis and survival (9) (10) (11) (12) (13) . Indeed, TN is an extremely permissive substrate for glioma migration in a two-dimensional (2D) matrix (14) .
Using a three-dimensional matrix of type 1 collagen (3D-CL) gel as a physiological environment to examine glioma invasiveness (15-17), we described previously that the addition of TN increased the invasiveness of glioma cells and that an associated mechanism is the downstream production of MMP-12 (18) . What is not known is the signaling cascade that links TN with MMP-12 and that regulates glioma invasiveness.
Multiple signal transduction pathways are aberrantly activated in malignant gliomas, including the RAS-MAP kinase pathway, PI3K-AKT-mTOR axis and protein kinase C (PKC). A large body of evidence suggests a critical role of PKC in the malignant phenotype of gliomas. High PKC enzyme activity is correlated with the proliferation rate of glioma lines in culture and PKC inhibitors reduce glioma proliferation (19) . Hyperactive or overexpressed PKC is considered to be a prominent characteristic of malignant brain tumors (20, 21) . Moreover, PKC has been implicated not only in cellular proliferation but also in the elevated migratory, invasive, survival and angiogenic characteristics of glioma cells (22) (23) (24) (25) .
PKC is a family of serine/threonine kinases comprising 12 members (26) . PKC isozymes are classified into three subgroups based on cofactor requirement for activation. Conventional PKCs (a, b1, b2 and c) require Ca 2þ , diacylglycerol and phospholipids such as phosphatidylserine for full activation. Novel PKCs (d, e, g, h, m and l) are Ca 2þ independent. Atypical PKCs (ï and f) are both Ca 2þ and diacylglycerol independent. Inhibitors of PKC with higher selectivity to subgroups are available. These include calphostin C [inhibitory concentration (IC 50 ) 5 50 nM] with selectivity for conventional and novel but not atypical isoforms (27) , G0 6976 with selectivity toward PKCa isozymes [IC 50 5 2.3 nM] (28) and rottlerin with selectivity for PKCd [IC 50 5 3-6 lM] (29). Pan PKC inhibitors that do not discriminate between isozymes also exist and they include bisindolylmaleimide (30) . Using these inhibitors and other tools, the present study investigated the signaling mechanisms involved in the TN-stimulated glioma invasiveness in 3D-CL matrix and the correspondent production of MMP-12. Our results implicate PKCd as a mediator of these activities.
Materials and methods

Cell culture
The U178 or U251 human glioma cell line was originally obtained from American Type Culture Collection (Manassas, VA) and maintained in minimum essential medium supplemented with 10% fetal bovine serum. For three-dimensional (3D) cell culture, we prepared type 1 collagen (CL) gel on ice as per manufacturer's instruction (Chemicon, Temecula, CA). Briefly, for preparing 500 ll of CL gel, 400 ll of cold CL solution was mixed with 100 ll of cold 5Â Dulbecco's modified Eagle's medium and the mixture was pH neutralized. Unless otherwise stated, 1 million glioma cells were added to 500 ll of CL solution, supplemented with or without test molecules (such as TN or PKC inhibitors). The plate was kept immediately at 37°C for 1 h for polymerization, trapping cells within the CL. After the CL gel had formed and become a 3D-CL matrix, it was covered with culture media. CL was used to generate a 3D matrix because it readily formed the gel when warmed to 37°C and into which glioma cell could be embedded. Importantly, CL is an ECM molecule expressed around glioma cells in situ (31, 32) .
Invasion assays
Glioma cells were trypsinized with 0.25% trypsin-ethylenediaminetetraacetic acid and were suspended in CL solution as described above. Test molecules including TN (10 lg/ml) were added into the CL solution. The TN (CC065, Chemicon) used in the present study was human TN-C protein with a molecular weight around 280-300 kDa. Following pipetting to mix cells and test molecules into the CL solution, 70 ll (140 000) of cells were distributed onto the center of the top compartment of Transwell migration chambers [Costar 3422, polycarbonate membrane, 24-well format, 8 lm pore size (Corning, Corning, NY)] (18) . Following polymerization of the CL I droplet, 100 ll of Dulbecco's modified Eagle's medium/F-12 medium with N2 supplement was added to the upper chamber and 1 ml of 10% fetal bovine serum-containing medium was applied to the lower well. Cells were then allowed to invade out of the 3D-CL matrix, across the membrane, at 37°C for 24 h. Non-invasive cells were removed from the top compartment of the Transwell with a cotton swab and the invasive cells present on the underside of the membrane were fixed and stained with hematoxylin. The number of invasive cells was counted per field (Â40 microscope objective) from four random fields of each membrane.
Abbreviations: IC 50 , inhibitory concentration; MMP, matrix metalloproteinase; PBS, phosphate-buffered saline; PKC, protein kinase C; PMA, phorbol-12,13-myristate acetate; RNAi, RNA interference; siRNA, small interfering RNA; TN, tenascin-C; 3D, three-dimensional; 3D-CL, three-dimensional matrix of type 1 collagen; 2D, two-dimensional. When PKC inhibitors were used, they were added within the gel and also in the medium in the upper and lower chambers of the Transwell. The concentration of inhibitors described in the Results refers to the final concentration within the gel and culture medium.
Subcellular fractionation and translocation of PKC isoforms in 3D-CL matrix Glioma cells (5 Â 10 6 ) were suspended into 500 ll of cold CL gel solution and plated onto a well of a 24-well plate. Cell-gel solution was supplemented with or without test molecules (e.g. TN) and was allowed to polymerize at 37°C as described earlier. The polymerized gel was then covered with 300 ll of Dulbecco's modified Eagle's medium/F-12 (N2 supplemented) medium. Inhibitors of PKC were added to the medium as well as within the gel; the PKC activator, phorbol-12,13-myristate acetate (PMA), was similarly utilized. At desired time points, media was removed and 500 ll of digitonin lysis buffer (1 M Tris-HCl, pH 7.5, 100 mM ethyleneglycol-bis(aminoethylether)-tetraacetic acid, 100 mM ethylenediaminetetraacetic acid, 100 mg/ml digitonin, 100 mM NaF, 100 mM sodium orthovandate; protease inhibitors were added to the buffer immediately before use) was added to the gel. With repeated pipetting, the CL gel disintegrated and the resulting cloudy solution was homogenized for 10 s in a homogenizer. Cells were further lysed by sitting on ice for 10 min. Next, the cell lysate was ultracentrifuged at 100 000g for 45 min at 4°C. The supernatant was collected as the cytosolic fraction of cells. The pellet was suspended in 60 ll of digitonin-Triton-X lysis buffer (digitonin lysis buffer supplemented with 1% Triton X-100), incubated on ice for 30 min, centrifuged for 10 min at 10 000g at 4°C and the resulting supernatant was collected as the particulate (membrane) fraction. The total protein concentration of each fraction was determined using the Bio-Rad protein assay. Equal amounts of protein (50 lg) from each fraction were resolved on 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis for western blot analysis.
PKCd activity assay following immunoprecipitation
Equal amount of total cellular protein (500 lg/ml) from each subcellular fraction was incubated with 20 ll (4 lg) of PKCd antibody (C-17-SC 213, Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at 4°C. Twenty microliters of protein A/G plus-Agarose beads were added and incubated at 4°C on a rotating device overnight. The immunoprecipitate was collected by centrifugation at 2500 r.p.m. for 5 min at 4°C. The pellet was washed three times with 1 ml of lysis buffer and once with phosphate-buffered saline (PBS).
Immunocomplex-bearing beads as collected by centrifugation were washed with sample preparation buffer (50 mM Tris-HCl, 50 mM b-mercaptoethanol, 10 mM ethyleneglycol-bis(aminoethylether)-tetraacetic acid, 10 mM benzamidine, 5 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, pH 7.5) followed by kinase buffer [25 mM Tris-HCl (pH 7.5), 5 mM b-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na 3 VO 4 , 10 mM MgCl 2 and 200 lM adenosine triphosphate]. After a final wash, the immunocomplex bearing beads were suspended in kinase buffer and their PKCd activity was quantified by measuring the dye-labeled phosphorylated substrate using a colorimetric PKC Activity Assay Kit as per manufacturer's instruction (Calbiochem, Mississauga, Ontario, Canada). Following color development, the absorbance was measured at 492 nm in a microplate reader to quantify the PKC-dependent phosphorylated peptide. The absorbance is directly proportional to the PKC activity.
Immunofluorescence for PKCd Cells embedded in 3D-CL gel supplemented with or without PMA or TN were grown for 1 h at 37°C. Gels were then washed with PBS followed by fixation with 4% paraformaldehyde for 15 min at room temperature. The 3D-CL gels were rewashed with PBS and glycine (0.15 M in PBS) was added for 10 min to quench the formaldehyde. The gels were washed in PBS for 10 min, and 0.02% Triton X-100 in PBS was then added to permeabilize cells. A primary rabbit antibody to PKCd (C-17, Santa Cruz Biotechnology) was added to the gel overnight at 4°C. Following washes, gels were incubated with an Alexa 488 conjugated anti-rabbit secondary antibody for 1 h. Finally, each gel was placed onto a glass cover slip with mounting medium.
Images were captured using a Leica DMRBE microscope with a Â20 objective using a spot charge-coupled device camera.
Western blot analyses
To determine the translocation of PKCa or PKCd, subcellular fractions were prepared from the cell lysates as described above. Equal amounts of protein from each fraction were resolved on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis for western blot analysis. MMP-12 was either analyzed from the conditioned media or immunoprecipitated from cell-conditioned medium, electrophoresed in 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (for MMP-12) under reducing conditions and transferred to polyvinylidene difluoride membrane (Millipore, Bedford, MA). The latter was blocked with 10% milk in saline overnight and was then probed for 24 h with either rabbit anti-PKCa, anti-PKCd or MMP-12 (Ab 19052) (Chemicon). Secondary antibodies (anti-rabbit horseradish peroxidase; 1:10 000) were added for 1 h, and bands were detected using enhanced chemiluminescence detection kit (Amersham Bioscience, Piscataway, NJ) and a gel documentation system.
Gelatin Zymography
Gelatin zymography to determine the amounts of pro-and active-MMP-2 has been described elsewhere (8) .
PKCd small interfering RNA Three predesigned small interfering RNAs (siRNAs; 25 oligonucleotides in length; Invitrogen, Burlington, ON, Canada), designated siRNA1, siRNA2 and siRNA3, were used to target human PKCd. For siRNA1, the sequence was 5#-GGUGAAGCAGGGAUUAAAGUGUGAA-3#. The sequences for siRNA2 and siRNA3 were 5#-GACAUCCUGGAGAAGCUCUUUGAAA-3# and 5#-GCCAUCCACAAGAAAUGCAUCGACA-3#, respectively. Two stealth RNA interference (RNAi) scrambled control duplexes containing either medium or low guanine cytosine content were used to serve as negative controls for the RNAi response. The sequences for the RNAi controls have no significant homology to any known gene sequences from mouse, rat or human.
For transfection with siRNA, glioma cells were plated in 24-well plates and were incubated with 33 nM siRNA and lipofectamine (Invitrogen), as described previously for RNAi experiments (18) . After 48 h, cells were harvested for invasion assay or MMP-12 detection as described above.
Statistics
The one-way analysis of variance test with post hoc Tukey-Kramer multiple comparisons was used.
Results
In 3D-CL matrix, the TN-stimulated glioma invasiveness is reduced by inhibitors of PKC In previous work (18), we found that when encased in a 3D-CL matrix supplemented with TN, glioma cells increased their movement out of the CL gel onto the other side of a filter where their numbers could be quantified as an index of glioma invasiveness. To determine whether or not the PKC pathway was involved in TN-stimulated glioma invasiveness in 3D-CL matrix, we employed pan-specific (bisindolylmaleimide) or conventional and novel PKC-selective (calphostin C) inhibitors. We found that the number of U178 glioma cells that invaded across the TN-supplemented CL matrix was reduced by both inhibitors (Figure 1 ), which is also the case for U251 glioma cells (supplementary Figure 1 is available at Carcinogenesis Online). This reduction occurred at concentrations known to inhibit PKC and was not due to toxicity of bisindolylmaleimide or calphostin C as determined through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (data not shown). When the U178 and U251 lines were allowed to invade across the 3D-CL matrix in absence of TN, glioma invasiveness was not altered in presence of inhibitors (supplementary Figure 2 is available at Carcinogenesis Online). These data suggest that PKC isoforms were engaged in glioma invasiveness in a 3D-CL matrix only when TN was present.
PKCa does not have a major role in TN-stimulated glioma invasiveness
From the observation that bisindolylmaleimide or calphostin C decreased TN-stimulated glioma invasiveness in 3D-CL, we next sought to determine the involvement of particular PKC isozymes. We first employed G0 6976, described as a selective inhibitor for PKCa (28) . Although the addition of G0 6976 into the CL þ TN 3D matrix decreased invasiveness of U178 glioma cells, the apparent IC 50 (over 100 nM) to reduce invasiveness was beyond its reported IC 50 value (2.3 nM) for inhibiting conventional PKC isozymes (Figure 2A ). Similar result was also observed with U251 line (supplementary Figure 3 is available at Carcinogenesis Online). These results imply the minor involvement of PKCa in TN-stimulated glioma invasiveness, which was supported by the observation that TN did not translocate PKCa from the cytosol to the particulate (membrane) fraction of cells ( Figure 2B ). Translocation of PKC isozymes is an index of their activation and the positive control PMA translocated PKCa from the cytosolic to the particulate fraction after 1 h ( Figure 2B ).
PKCd appears important for TN-stimulated glioma invasiveness in 3D-CL matrix
The result that PKCa is not a major mediator of TN-stimulated glioma invasiveness, coupled with the absence of other conventional PKC isoforms in our glioma lines (33, 34) , led us to examine novel PKC isoforms. We found that TN did not translocate PKCe either after 1 or 3 h (data not shown). In contrast, PKCd was prominently translocated in cell fractionation studies by TN, to the extent achieved by the 
. TN-stimulated glioma invasiveness is reduced by PKC inhibitors. Tenascin-C (henceforth denoted as TN in this and all figures) that is embedded within CL gels increased invasiveness of U178 glioma cells (A and B);
a P , 0.001of CL þ TN compared with CL alone. The addition of bisindolymaleimide or calphostin C to TN-supplemented CL gels (CL þ TN) decreased invasiveness ( ÃÃÃ P , 0.001 compared with CL þ TN) (A and B). Columns represent the mean ± SEM of four analyses and the result was reproduced across another set of experiment. Panel (C) depicts pictorially the effect of calphostin C on glioma invasiveness after 24 h (original magnification Â400). Fig. 2 . PKCa plays a minor role in TN-stimulated glioma invasion. The TN-increased invasiveness of U178 glioma cells ( a P , 0.001of CL þ TN compared with CL alone) was attenuated in a concentration-dependent manner by the PKCa selective inhibitor, G0 6976 (A). However, the effective concentrations of G0 6976 to reduce invasion were mostly beyond its IC 50 value of 2.3 nM (28) to inhibit PKCa enzyme activity; ÃÃ P , 0.01, ÃÃÃ P , 0.001 compared with CL þ TN. Columns are mean ± SEM of four wells and the result was reproduced in another set of experiment. In panels (B), western blot analysis was conducted of the subcellular distribution of PKCa between cytosolic and membrane particulate (P) fractions of U178 glioma cells following phorbol ester (PMA, positive control) or TN treatment of cells grown in CL gel. Protein extract collected after 1 or 3 h following PMA or TN treatment were used. Equal amount of proteins were loaded in each well. While PKCa was translocated following PMA treatment, TN did not produce translocation of PKCa after 1 h and minimally after 3 h. Cell lysate obtained at 0 h served as additional control of the basal level of PKCa in cells. Actin was used as loading control for respective cytosolic or particulate fractions. This experiment was reproduced twice.
Tenascin-C mediated glioma invasion and PKC potent PKC stimulator, PMA ( Figure 3A) . The involvement of PKCd was further supported by the increase in PKCd enzymatic activity in response to TN stimulation in the 3D-CL matrix ( Figure 3B) .
We next performed immunofluorescence analyses to investigate whether the translocation of PKCd could be detected at the level of individual cells. Figure 3C shows that while PKCd immunofluorescence was diffusely distributed across cells when grown in a CL matrix, the addition of TN resulted in accumulation of PKCd at the plasma membrane, in a manner similar to that found when PKC of cells were activated by the positive control PMA.
A selective inhibitor of PKCd decreases TN-stimulated glioma invasion and MMP-12 expression
To further investigate the involvement of PKCd in TN-stimulated glioma invasiveness, we employed rottlerin, a relatively selective inhibitor of PKCd (35) . The addition of rottlerin to the CL þ TN 3D matrix significantly decreased U178 glioma cell invasiveness in a concentration-dependent manner ( Figure 4A ) and time-dependent manner ( Figure 4B ) without any obvious toxicity (data not shown).
Rottlerin also decreased the invasiveness of U251 glioma cells (supplementary Figure 4 is available at Carcinogenesis Online).
We addressed whether inhibition of PKCd would alter MMP-12 expression. Figure 5A shows that the addition of rottlerin to the CL þ TN matrix reduced TN-stimulated MMP-12 expression as detected in either cell-conditioned media or from immunoprecipitates. These results of PKCd inhibition provide an important link between TN exposure and MMP-12 production downstream.
siRNA experiments further validate that reduction of PKCd attenuates glioma invasiveness and MMP-12 expression The likelihood that TN-mediated glioma invasiveness involves PKCd was next examined by RNA interference. Figure 5B shows that the three different siRNAs to PKCd reduced PKCd protein level in glioma cells; in contrast, PKCa and e levels were not affected (data not shown). In addition, knock down of PKCd with siRNA reduced MMP-12 expression. Concordantly, glioma invasiveness promoted by TN in 3D-CL matrix was attenuated by PKCd RNAi treatment ( Figure 5C ). Fig. 3 . PKCd is promptly activated in glioma cells by TN encased within the CL gel. Western blot analysis of cytosolic (C) and particulate (P) fractions of glioma cells showed translocation of PKCd by TN in CL gel compared with CL alone; the translocation was observed after 1 h and was more prominent at 3 h (A). PMA was used as a positive control for translocation of PKC isoforms. When the same amount of cellular protein from each subcellular fraction was used for immunoprecipitation for PKCd, and the immunoprecipitate was then used for assay of PKC activity (B), we determined that increased PKCd activity was in the particulate fraction of TN-treated cultures compared with CL alone; ÃÃÃ P , 0.001 compared with CL. In Panel (C), U178 glioma cells in CL gels supplemented with TN or PMA for 1 h were stained for PKCd (green). An increased level of PKCd immunofluorescence (insert is of higher magnification) was observed on the cell membrane of cells treated with TN compared with control, providing further support of the translocation of PKCd with TN. Cell nuclei were stained with Hoescht dye (blue) and the merged image is displayed on the right. Images were captured at Â200 original magnification.
S.Sarkar and V.W.Yong Discussion
An extensive deposit of various ECM molecules surrounds glioma cells in situ, where they regulate the behavior of transformed and non-transformed cells alike. Among the various ECM molecules, TN appears to be very important for glioma pathophysiology, as its expression level correlates inversely with prognosis and survival of patients (9) (10) (11) (12) . In a series of 62 cases, gliomas with diffuse intercellular TN immunoreactivity showed higher proliferation index than those with focal and limited expression (36) . A monoclonal antibody to TN that was labeled with 131 I slowed tumor growth and prolonged survival in rodents implanted in the flank or brain with human glioma cells (37, 38) . The 131 I-labeled anti-TN antibody has since been tested in a pilot trial in patients with malignant glioma where encouraging survival results have been obtained (39) . Other means to target TN in gliomas, such as by the use of siRNA, are being tested (40) .
In a 2D culture system, TN was found to be very permissive for the migration of glioma cells (16) . Of several ECM proteins found in gliomas and tested for their ability to induce the haptotaxis of human neural stem cells in 2D, in work that attempts to elucidate interactions in the glioma microenvironment, TN was found to be the most potent (41) . Taking into consideration that a 3D matrix is a more physiological environment to evaluate cell behavior, we have examined and reported that TN encapsulated within 3D-CL promoted the invasiveness of glioma cells out of the 3D constraint through an MMP-12-dependent mechanism (18) . To characterize this further, the present study has attempted to determine the signal transduction pathways through which TN in 3D-CL regulates MMP-12 expression and glioma invasiveness. Such investigations may provide additional targets to inhibit TN-mediated glioma pathophysiology.
We have implicated the PKC system, particularly PKCd, in the TN-simulated MMP-12 production and glioma invasiveness. This (Figures 1 and 2 , and S. Sarkar, V.W.Yong, unpublished data), we found no evidence for the involvement of PKCa or PKCe in TN-mediated glioma invasiveness in the 3D context. Our findings raise the possibility that glioma invasiveness promoted by TN may be reduced not only by MMP-12 or TN inhibitors but also by agents that attenuate PKCd level or activity.
The PKC enzyme system has been implicated by several groups including our own in various aspects of glioma biology, such as invasiveness, proliferation, MMP expression, apoptosis and survival (42, 43) . In this regard, it appears that depending on the microenvironment that it encounters, a glioma cell may utilize different PKC isoforms to achieve particular functions. For example, in a 2D format that is not constraint by ECM proteins, PKCe appears to regulate migratory behavior (33, 34) . In contrast, in the present study where glioma cells are encased within a 3D-CL matrix supplemented with TN, we found no evidence for the involvement of PKCe; rather, PKCd was prominently engaged. Moreover, while PKCa has been implicated in glioma invasiveness in a 2D context (44), we did not find evidence for its role in regulating invasiveness in the TN-CL 3D matrix. Given the close correlation between glioma pathophysiology and TN expression in vivo, we would suggest that it is more critical to target PKCd rather than other PKC isoforms against glioma invasiveness.
The complexity of glioma cells engaging specific PKC isoform depending on the microenvironment has also been noted for other tumors, probably because of the many different roles and mode of regulation of PKC isozymes that vary among many different cell types (45) . Nonetheless, PKCd has been implicated in invasiveness of other tumor types, such as in breast cancer (46, 47) . Clearly, the role of the different isoforms of PKC in glioma cells, and how they regulate the many different pathways involved in malignant transformation (48), Tenascin-C mediated glioma invasion and PKC deserves further attention. In this regard, it is encouraging that PKC inhibitors continue to be the subject of clinical trials in gliomas (49) .
In summary, our results implicate PKCd in the mechanism of TNpromoted MMP-12 expression and glioma invasiveness. The results are potentially relevant to glioma therapeutics since TN is an ECM protein very prominently associated with glioma pathophysiology. Several questions remain, including the cell surface receptors that transduce signals from TN to intracellular PKCd, and the precise mechanisms by which PKCd links to MMP-12 generation. These questions are the subject of future studies that aim to improve the prognosis of patients with malignant gliomas.
Supplementary material
Supplementary Figures 1-4 can be found at http://carcin. oxfordjournals.org/
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Canadian Institutes of Health Research. The pro-and active forms of MMP-2 present in cell-conditioned media were evaluated by gelatin zymography to provide evidence of equal loading between the groups since MMP-2 was not found to be altered by TN treatment in previous reports (18) . In panel (B), three siRNAs targeted toward different regions of PKCd reduced expression of PKCd as detected by western blot analyses; in contrast, PKCa or e levels were not reduced (data not shown). In addition, decreased level of MMP-12 was detected in the same extracts (B). glioblastoma multiforme refers to a resected human glioma homogenate. When PKCd siRNA-treated cells were allowed to invade through TN-supplemented collagen gels (CL þ TN), their invasiveness was attenuated compared with control siRNA-treated cells (C); ÃÃ P , 0.01, ÃÃÃ P , 0.001 compared with control siRNA.
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